|Cystic fibrosis (Tutorial)|
|Link to Commons|
|Steps for video creation|
|Step 1||Preview my changes (10 sec)|
|Step 2||Upload to Commons (10 min)|
Mechanism of genetic defect
It is caused by the presence of mutations in both copies of the gene for the cystic fibrosis transmembrane conductance regulator, (or CFTR) protein.
Those with a single working copyof CFTR, are carriers, and otherwise mostly normal.
Systems affected by genetic defect
Effects of genetic defect
When the CFTR is not functional, secretions which are usually thin, become thick.
The condition is diagnosed by a sweat test, and genetic testing. In parts of the world, where the defect in the gene is very common, screening of infants at birth with a sweat test may take place.
There is no known cure for cystic fibrosis, and the most common complications come from lung infections.
Treatment of pneumonia
Prevention of lung infections
Pancreatic enzyme replacement
CF is most common among people of Northern European ancestry, and affects about one out of every 3,000 newborns. In addition, about one in 25 people in Northern Europe is a CF gene carrier. The disease is least common in Africans, and Asians.
- O'Sullivan, BP; Freedman, SD (30 May 2009). "Cystic fibrosis". Lancet. 373 (9678): 1891–904. doi:10.1016/s0140-6736(09)60327-5. PMID 19403164.
- Hodson, Margaret; Geddes, Duncan; Bush, Andrew, eds. (2012). Cystic fibrosis (3rd ed.). London: Hodder Arnold. p. 3. ISBN 978-1-4441-1369-3. Archived from the original on 2017-09-08. CS1 maint: discouraged parameter (link)
- Massie, J; Delatycki, MB (December 2013). "Cystic fibrosis carrier screening". Paediatric Respiratory Reviews. 14 (4): 270–5. doi:10.1016/j.prrv.2012.12.002. PMID 23466339.
- Buckingham, Lela (2012). Molecular diagnostics fundamentals, methods, and clinical applications (2nd ed.). Philadelphia: F.A. Davis Co. p. 351. ISBN 978-0-8036-2975-2. Archived from the original on 2017-09-08. CS1 maint: discouraged parameter (link)
- Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D (2004). "Cystic fibrosis adult care consensus conference report". Chest. 125 (90010): 1–39. CiteSeerX 10.1.1.562.1904. doi:10.1378/chest.125.1_suppl.1S. PMID 14734689.
- Warnock, L.; Gates, A. (21 December 2015). "Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis". The Cochrane Database of Systematic Reviews (12): CD001401. doi:10.1002/14651858.CD001401.pub3. PMID 26688006.
- Ong, T; Ramsey, BW (15 September 2015). "Update in Cystic Fibrosis 2014". American Journal of Respiratory and Critical Care Medicine. 192 (6): 669–75. doi:10.1164/rccm.201504-0656UP. PMID 26371812.
- Nazareth, D; Walshaw, M (October 2013). "Coming of age in cystic fibrosis - transition from paediatric to adult care". Clinical Medicine. 13 (5): 482–6. doi:10.7861/clinmedicine.13-5-482. PMC 4953800. PMID 24115706.
- Andersen DH (1938). "Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathological study". Am J Dis Child. 56 (2): 344–399. doi:10.1001/archpedi.1938.01980140114013.